• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Pharmaceuticals - Global Outlook Product Image

Pharmaceuticals - Global Outlook

  • ID: 661656
  • January 2012
  • Region: Global
  • 443 Pages
  • Global Industry Analysts, Inc

The global outlook series on Pharmaceuticals provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. Punctuated with 46 statistically rich tables, the report provides an overview of the pharmaceutical industry, and highlights global trends impacting the marketplace, such as patent expiry of blockbuster global drugs, increasing biogenerics, among others. The report offers an in-depth analysis of the pharmaceutical industry, highlights latest trends and demand drivers, the recent FDA approvals, the current and the impending patent expiries, in addition to providing statistical insights.

The report also recapitulates recent noteworthy mergers, acquisitions, and other strategic developments. The report briefly discusses the pharmaceutical market outlook across various markets worldwide. Regional markets extensively discussed in the report include the United States, Canada, Japan, China, Germany, South Korea and India, among several others. Also included is an indexed, easy-to-refer, fact-finder directory listing the addresses, and contact details of 2,589 companies worldwide.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying.

PHARMACEUTICALS

A GLOBAL OUTLOOK, JANUARY 2012

CONTENTS

1. GLOBAL OUTLOOK 1
Global Pharmaceutical Market - Hit, but Not Down 1
Cost Containment and Patent Expirations Affect Market Growth 1
Industry Seeks Measures to Sustain Future Growth 2
Outlook Remains Positive, Yet Tempered 2
Table 1: World Recent Past, Current & Future Analysis for
Prescription Pharmaceutical Market by Geographic Region - US,
Canada, Japan, Europe, Asia-Pacific, Latin American and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Billion for Years 2010 through 2015 3

Table 2: World 5-Year Perspective for Prescription
Pharmaceuticals by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific,
Latin America and Rest of World Markets for Years 2011 and
2015 4
Oncologics - The Largest Drug Class in the Global Prescription
Pharmaceutical Market 5
Table 3: World Recent Past, Current & Future Analysis for
Prescription Pharmaceuticals by Therapeutic Class -
Angiotensin II Antagonists, Antidepressants, Antidiabetics,
Anti-epileptics, Antipsychotics, Anti-ulcerants, Autoimmune
agents, Lipid Regulators, Oncologics, Respiratory Agents and
Others Markets Independently Analyzed with Annual Sales
Figures in US$ Billion for Years 2010 through 2015 6

Table 4: World 5-Year Perspective for Prescription
Pharmaceuticals by Therapeutic Class - Percentage Breakdown
of Dollar Sales for Angiotensin II Antagonists,
Antidepressants, Antidiabetics, Anti-epileptics,
Antipsychotics, Anti-ulcerants, Autoimmune agents, Lipid
Regulators, Oncologics, Respiratory Agents and Others Markets
for Years 2011 and 2015 7
Major Challenges Faced by the Global Pharma Industry 8
Key Opportunities 8
Generic Drug Sales Soar 8
Authorized Generics - A Major Concern for Generic Makers 8
Increasing Focus on Emerging Markets 8

2. MARKET TRENDS 10
Pharmaceutical Industry Fares Relatively Well During Recession 10
Fallout of Recession on the Pharmaceutical Market - Largely an
Indirect Effect 10
Patent Cliff Hurts Pharma Industry, Brings Smiles on the Faces
of Payers 10
The Patent Cliff: Select Major Drugs Going Off-Patent during
2011-2015 11
Cost Containment Comes as a Double Blow to the Global Pharma 12
Global Pharma Alters Strategy - Lays More Emphasis on
Specialty Areas 12
Innovation Continues in R&D Methods 12
Aging Population - A Major Driver of Pharmaceutical Growth 12
Market Booming for Old Age Related Medications 13
Rising Prominence of Biopharmaceuticals 13
Select FDA-Approved Biopharmaceuticals in 2010 14
Biotech Future Appears Bright 14
Focus on OTC Drugs Rising 14
Manufacturers Dump Conventional Approaches to Play Safe 15
High Fragmentation Typifies the Global Generic Drug Sector 15
Table 5: Leading Companies in the Global Generic Drugs Market
(2010): Percentage Breakdown by Value Sales for Teva
Pharmaceutical Industries, Sandoz, Mylan Laboratories,
Watson, Ratiopharm, and Others 15
Significant Potential for Consolidation Activity Exists in the
Generic Drug Sector 16
Global Majors Chart Acquisition Route in Developing Economies 16
Expanding Opportunities through In-Licensing 16
Differentiation & Innovation - Key in the Competitive Market 17
Virtual Techniques March Ahead 17
Big Pharma Companies Cashing in on the Biosimilars Drive 17
Biosimilar Uptake in Developed Markets Thus Far 18
Technologies to Gear up Research 18
Cloud Computing to Better Pharmaceutical Sector 18
Biotherapies to Drive Growth in Cancer Therapy Market 19
Oncology Drugs - the Leader in the Global Pharma Pipeline 19
Vaccine Demand on the Rise 19
China and India Emerge as Major Contract Manufacturing Hubs 20
Global Analgesics Market to Soar 20
Nano-Enabled Drug Discovery Geared to Lead 20
Proteomics - The Current Spotlight 21
Neurodegeneration Treatments Identified in Research 21

3. MAJOR ISSUES/CHALLENGES 22
Horde of Issues Bog Down Global Pharma Industry 22
Challenges Abound in OTC Business for the Pharma Industry 22
High Cost of Pharmaceuticals Challenge Large Scale Adoption 22
Regulatory Pressures - A Bone of Contention 22
Big Pharma R&D Pipelines are Drying Up 23
Legal and Infrastructure Hurdles in Emerging Markets - A
Concern for Global Pharma Industry 23

4. COMPETITIVE LANDSCAPE 24
Consolidation Activity Remains Rife 24
Table 6: Global Pharmaceutical M&A Activity in Transaction
Volume by Country/Region: 2010 24

Table 7: Global Pharmaceutical M&A Activity in Transaction
Value by Country: 2010 24

Table 8: Global M&A Activity by Therapeutic Area (2010):
Percentage Breakdown of Number of Deals for Oncology,
Cardiovascular, Central Nervous System, Dermatology,
Gastro-Intestinal and Others 25

Table 9: Select Acquisitions in the Pharmaceutical Industry
Worldwide: 2011 25
Table 10: Select Acquisitions in the Pharmaceutical Industry
Worldwide: 2010 26
Leading Pharma Companies 27
Table 11: Leading Pharmaceutical Manufacturers Worldwide by
Revenues: 2009 & 2010 27
Major Products 27
Table 12: Leading Pharmaceutical Products Worldwide by Sales:
2009 & 2010 27

5. MERGERS AND ACQUISITIONS ACTIVITY IN THE PHARMA INDUSTRY 28

6. STRATEGIC CORPORATE DEVELOPMENTS 63

7. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST 79

8. PRODUCT APPROVALS/LAUNCHES 82

A REGIONAL MARKET PERSPECTIVE 92

1. THE UNITED STATES 92
US Market Outlook 92
Recession Impacts US Pharma Industry 92
Generic Drugs Dominate in Prescriptions, Share Still Languish
in Value 92
Table 13: Leading Companies in the US Generic Drugs Market
(2010): Percentage Breakdown by Value Sales for Teva
Pharmaceutical Industries, Mylan Laboratories, Watson,
Sandoz, Mallinckrodt and Others 93
Biopharmaceuticals - The New Rage for US Pharma 93
Biopharmaceutical R&D Expenditure Stays Positive
Loses Pace 93
Table 14: R&D Expenditure In the US Pharmaceutical Industry:
2006-2010 94
FDA Approvals Rise after Prolonged Stagnancy 94
Select Major New Drugs Approved by FDA in 2011 94
Select Major New Drugs Approved by FDA in 2010 95
What Lies Ahead of the Pharma Industry in the Wake of
Increasing Stress? 96
Drug Shortages Pose Enormous Challenges 96
US Biopharmaceutical Industry - R&D and Trade 97
Table 15: US Exports of Biopharmaceuticals: 2005-2010 97
Medicare - The Leading Expenditure Coverage Source in the US 98
Table 16: Prescription Drug Expenditure in the US by Payer
(2005 & 2010): Percentage Breakdown of Expenditure for
Medicare, Medicaid and Others 98
Competitive Scenario 98
Table 17: Leading Pharmaceutical Companies in the US by
Prescription Drug Revenue: 2009 & 2010 99

Table 18: Leading Pharmaceutical Companies in the US by Total
Prescriptions: 2009 & 2010 99
Leading Products 100
Table 19: Leading Prescription Drugs in the US by Value
Sales: 2009 & 2010 100

Table 20: Leading Prescription Drugs in the US by Dispensed
Prescriptions: 2009 & 2010 101

Table 21: Leading Generic Drugs in the US by Total
Prescriptions: 2010 102

Table 22: Leading Brands in the US Eye/Lens Care Solutions
Market by Value Sales at Drug Stores: 2009 102

Table 23: Leading Brands in the US Eye/Lens Care Solutions
Market by Unit Sales at Drug Stores: 2009 103
Pharmaceutical Distribution 103
Table 24: US Prescription Pharmaceutical Market by
Distribution Channel (2009 & 2010): Percentage Breakdown of
Revenues for Chain Stores, Mail Service, Independent Stores,
Clinics, Private Hospitals and Others 103

Table 25: US Prescription Pharmaceutical Market by
Distribution Channel (2009 & 2010): Percentage Breakdown of
Total Prescriptions for Chain Stores, Independent Stores,
Food Stores and Others 104

2. CANADA 105
Canadian Pharmaceutical Market to Grow Steadily 105
Canadian Pharmaceutical Industry - An Overview 105
Retail Prescriptions Rise in Canada 105
Generic Drugs Continue to Capture Higher Market Share 106
Pharmaceutical Spending Reaches Calamitous Levels in Canada 106
Table 26: Share of Expenditure on Drugs in the Total Canadian
Healthcare Expenditure (1975-2010) 107
Is Excessive Supply a Cause of Higher Drug Spending in Canada? 107
Regulations on Generic Drugs in Canada 107
Key Statistics 108
Table 27: Leading Therapeutic Classes in the Canadian
Pharmaceutical Market by Total Prescriptions: 2008-2010 108

Table 28: Leading Drugs in the Canadian Pharmaceutical Market
by Total Prescriptions: 2008 & 2009 109

Table 29: Leading Companies in the Canadian Pharmaceutical
Market by Revenue: 2008 & 2009 110

3. JAPAN 111
Market Overview 111
Horde of Factors Result in Japanese Pharma Market Slowdown 111
Industry Endeavors to Catch up with Generic Fervor 111
New Initiatives in 2010 Drug Price Revision 112
Table 30: Japanese Generic Drug Market by Revenues: 2007-2011 112
Companies Struggle for Profitability amid Patent Expirations 112
Sluggish Domestic Demand Forces Japanese Companies to Seek
Overseas Opportunities 113
Japanese Government Presses for Increased Use of Generic Drugs 113
Competition 113
The Mergers and Acquisitions in the Industry 113
Major Acquisitions of Japanese Pharmaceutical Companies:
2007-2011 114

4. EUROPE 115
European Countries Gear Up for Cost Containment Measures 115
Table 31: European Recent Past, Current & Future Analysis for
Prescription Pharmaceuticals by Geographic Region - France,
Germany, Italy, UK, Spain and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Billion for Years 2010 through 2015 116

Table 32: European 5-Year Perspective for Prescription
Pharmaceuticals by Geographic Region - Percentage Breakdown
of Dollar Sales for France, Germany, Italy, UK, Spain and
Rest of Europe Markets for Years 2011 and 2015 117

4a. FRANCE 118
The French Pharmaceutical Market - An Overview 118
Measures in Place to Promote Cost Containment 118
Austerity Measures to Trim Pharmaceutical Market Size 118

4b. GERMANY 119
German Market Continues to Rise 119
Germany Mulls Over Various Cost Cutting Measures 119
Table 33: German Pharmaceutical Production by Value:
2001-2010 119

4c. ITALY 120
Italian Pharmaceuticals Sector Dogged by Various Factors 120
Government Support Key for Growth of Innovation 120
Mid-Sized Firms: to Rise in Prominence 120

4d. THE UNITED KINGDOM 121
Planned Cost Cuts to Suppress Growth 121
Is UK's Pharma R&D Strength in Danger? 121
Pfizer Continues to Rule the UK Pharmaceutical Market 122
Table 34: Percentage Share Breakdown of Sales in the UK
Pharmaceutical Market by Leading Players: 2010 122

4e. SPAIN 123
Cost-Containment Measures to Drub Market Growth 123
Patented Drugs Dominate the Market 123
Table 35: Spanish Pharmaceutical Market by Segment (2010):
Percentage Breakdown of Sales for Patent-Protected Drugs, OTC
Drugs and Generic Drugs 123
Spanish Government Votes for Generic Drugs 124
Pharmaceutical Expenditure Continues to Plummet 124
Reference Pricing in Spain Meets Tremendous Success 124

4f. SWITZERLAND 125
Swiss Pharmaceutical Market to Post Steady Growth 125
Generics Lie Low in Swiss Pharma Industry 125
Swiss Pharma Industry - A Major Global Exporter of
Pharmaceuticals 125
Appreciation of Swiss Franc Raises Concerns 125

4g. RUSSIA 127
New Insurance Scheme to Drive Market 127
New Laws Expand Government's Role in Pricing 127
Competition Remains High 127
Generic Drugs to Gain Rapid Uptake in Russia 127
Domestic Industry Emphasizes on Generic Drugs 128

4h. DENMARK 129
Pharmaceutical Spending Rises 129

4i. FINLAND 129
Aging Population Drives Finnish Pharmaceutical Market 129

4j. THE NETHERLANDS 130
Pricing Pressures Haunt Dutch Pharmaceuticals Market 130

4k. LITHUANIA 130
Imports - A Major Source of Pharmaceuticals in Lithuania 130
Private Share in Pharma Expenditure Soars 130

4l. NORWAY 131
Generics Begin to Gain Momentum 131

4m. KAZAKHSTAN 131
Kazakhstan's Pharma Market to Post Robust Growth 131

4n. SERBIA 132
Serbian Pharmaceuticals Market Challenged by Several Factors 132

4o. PORTUGAL 132
Uncertain Economic Conditions Mar Pharmaceuticals Sector in
Portugal 132

4p. POLAND 132
Polish Pharmaceutical Market to Witness Substantial Growth 132

4q. HUNGARY 133
Hungary's Pharmaceutical Sector on the Rise 133

4r. GREECE 133
Payment Woes Compel Drug Companies to Demand Cash-on-Delivery 133

5. ASIA-PACIFIC 134
Asia-Pacific - The Fastest Growing Regional Market for
Pharmaceuticals Worldwide 134
Table 36: Asia-Pacific Recent Past, Current & Future Analysis
for Prescription Pharmaceuticals by Geographic Region -
China, India and Rest of Asia-Pacific Markets Independently
Analyzed with Annual Sales Figures in US$ Billion for Years
2010 through 2015 135

Table 37: Asia-Pacific 5-Year Perspective for Prescription
Cards by Geographic Region - Percentage Breakdown of Dollar
Sales for China, India and Rest of Asia- Pacific Markets for
Years 2011 and 2015 136
Access to Pharmaceuticals - A Major Impediment to Asian Pharma
Market Growth 136
Lipitor - The Leading Brand in the Asia-Pacific Pharmaceutical
Market 136
Table 38: Leading Pharmaceutical Products in Asia by Revenue:
2009 137

5a. CHINA 138
Chinese Pharmaceutical Market Posts Remarkable Growth 138
Economic Growth Drives Pharmaceutical Expenditure 138
Chinese Pharmaceutical Industry Makes a Mark for Itself 138
Industry Outlook Remains Robust 139
Government Increases Industry Scrutiny 139
Chinese Pharmaceutical Industry Surges amid Recession 139
A Strong, Innovative Pharmaceutical Industry in the Making 139
Increasing Opportunities for Multinational Companies in China 140
Chinese Company Makes Foray into the US 140
Chinese CRO Market Grows at a Robust Pace 141
Government Investments Imperative to Realize Strong Industry
Growth 141
Big MNCs Eye Chinese Pharmaceutical Industry 141
Major Challenges 142
Government's Pricing Reforms Puts Multinational Pharma
Companies in a Quandary 142
China Faces New Challenges and Short- Term Risks 143
Stringent Government Regulations Affects China's
Pharmaceutical Industry 143
Essential Drugs and Primary Healthcare Holds Discouraging
Prospects for Multinational Pharma Companies 143

5b. AUSTRALIA 144
Tough Economic Environment Hits Pharmaceutical Market 144
Market Drivers Remain Intact 144
Changes to PBS set to Result in Dramatic Changes in the Market 144
Table 39: Leading Pharmaceutical Products in Australia by
Revenue: 2009 145

5c. INDIA 146
Indian Pharma Market to Surge 146
Generics Lead the Market 146
Biopharmaceutical Segment Registers Strong Growth 146
Diabetes and Cancer Segments-To Lead Growth 146
Rapid Growth Ahead in the Indian Pharmaceutical Industry 146
Indian Generic Drug Producers to See High Demand from the US 147
India API Producers Eye Japanese Market 147
Government Offers Ample Support for Foreign Investment 147
Overseas Pharma Companies Follow Indian Counterparts to Gain
Market Share 148
Collaborations and Consolidation - A Major Strategy for India
Pharma Giants 148
Mergers and Acquisitions Dominate the Market Scenario 148
Major Acquisitions of Indian Pharmaceutical Companies/
Businesses in Recent Years 149
Cipla Tops Indian Pharmaceutical Market by Value 149
Table 40: Leading Indian Pharmaceutical Companies by Domestic
Sales: 2010 150
Cough Medication Tops Indian Pharmaceutical Sales Chart 150
Table 41: Leading Pharmaceutical Products in India by
Revenue: 2009 150
India Leads in DMF Filings in the US 151
Table 42: Leading DMF Filing Countries with the US FDA: 2009 151

5d. SOUTH KOREA 152
Exports of Pharmaceutical Products Surge, Imports Remain Far
Ahead 152
Government Sees Pharma as the Next Growth Engine (Korea) 152
Government Support, Key for Growth of Innovation 152
Clinical Trials Flourish in Korea 153
Table 43: South Korean Clinical Trial Market by Number of IND
Applications Approved by Korean Food and Drug Administration 153
Plavix Stands Ahead of Lipitor in Korea 153
Table 44: Leading Pharmaceutical Products in Korea by
Revenue: 2009 154

5e. THE PHILIPPINES 155
Pharmaceutical Market in the Philippines to Surge 155
Consolidation within the Pharmaceutical Sector on the Cards 155

5f. THAILAND 156
Generics - A Dominant Segment in the Thai Pharmaceutical Market 156
Thailand - A Growing Domestic Market for Pharmaceuticals 156

5g. MALAYSIA 157
Low Per-Capita Consumption Typifies Malaysian Pharmaceutical
Market 157
Market Bodes Tremendous Growth Prospects 157
Generics Dominate the Domestic Pharmaceutical Sector 157
A Peek into the Malaysian Pharmaceutical Industry 158
Major Drugs 159
Table 45: Leading Pharmaceutical Products in Malaysia by
Revenue: 2009 159

5h. PAKISTAN 160
Relatively Stable Environment to Surge Demand for Pharma Products 160
Pakistan - Still Not A Favorite Destination for Global Pharma 160
Exports Continue to Rise, Trade Balance Remains Negative 160
Lack of Price Revision - A Major Cause of Concern for Domestic
Industry 160
High Government's Share in Healthcare Spending Curbs Drug
Price Growth 161
Changing Government's View on Reimbursements to Offer Respite
to Market Growth 161

5i. VIETNAM 162
Growth Abounds in the Vietnamese Pharmaceutical Market 162
Increasing Drug Prices Leave Bitter Taste Among Patients 162
Vietnamese Pharmaceutical Market Fares Well During Recession 163
Industry Depends Immensely on Imports 163
Commitment to WTO Opens Vietnamese Market for Foreign Players 163
Pharmaceutical Imports Continue to Rise 164

5j. SRI LANKA 164
Sri Lankan Pharmaceutical Market - Going Strong 164
High Reliance on Imports - A Cause of Concern to the Industry 164

5k. SINGAPORE 165
Singapore - More Promising for Pharmaceutical Research Segment 165
Roche's Products Lead Singapore's Pharmaceutical Market 165
Table 46: Leading Pharmaceutical Products in Singapore by
Revenue: 2009 165

5l. INDONESIA 166
Overseas Companies Lose Ground in Indonesian Pharmaceutical
Industry 166

6. LATIN AMERICA 167
Latin American Pharmaceutical Market Surges Ahead 167
Generic Drug Market Picking Up in Latin America 167

6a. BRAZIL 168
Foreign Manufacturers Storm into Brazilian Pharmaceutical Sector 168

6b. ARGENTINA 169
Argentinean Pharmaceutical Market to Post Robust Growth 169
A Strong Domestic Industry Supports Argentinean Pharmaceutical
Market 169

6c. VENEZUELA 169
Market Overview 169

6d. MEXICO 170
Host of Factors to Restrain Future Growth in Market 170

6e. CHILE 170
Chilean Pharmaceutical Sector - A Snapshot 170

6f. COLOMBIA 171
Market Overview & Outlook 171

6g. PERU 171
Market Overview 171

6h. CUBA 172
Cuban Pharmaceutical Market - The Smallest in the Region 172

7. REST OF WORLD 173
Middle East and Africa Augurs Huge Growth Prospects for Global
Pharmaceutical Industry 173
Diverse Healthcare Systems in the MEA Region 173
Multinational Companies Flock MEA Region 173
Overview of Middle East Pharmaceutical Market 174

7a. SAUDI ARABIA 175
Saudi Arabia - A Lucrative Market in the Region 175
Generic Drugs - A Major Focus of the Domestic Industry 175
Presence of Overseas Players Increases in the Saudi
Pharmaceutical Industry 175
Pharmaceutical Exports on the Rise 176
Industry Battles Issues 176

7b. UNITED ARAB EMIRATES 177
A Glimpse of UAE Pharmaceutical Industry 177
Investments Remain a Lackluster Affair 177
Major Players 177
Recent Events Tighten Manufacturers' Profitability 178

7c. EGYPT 178
Overview 178

7d. JORDAN 179
Overview 179

7e. MOROCCO 179
Overview 179

7f. TURKEY 180
Overview 180

7g. OMAN 180
Overview 180

GLOBAL DIRECTORY

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos